LATEST NEWS    2009 | 2008| 2007| 2006

Visit this page often to get the latest news and updates on ITI.

2009 PRESS RELEASES

Immunomic Therapeutics’ Sub-Licensee Announces LAMP Cancer Vaccine Meets Phase I/II Endpoint, 14 of 20 Patients in Remission

December 11, 2009 Immunomic Therapeutics, Inc., (ITI) announced today that its sub-licensee, the Geron Corporation (Nasdaq: GERN), reported preliminary results from a Phase II study of GRNVAC1, a cancer vaccine for patients with acute myelogenous leukemia (AML).   A key feature of GRNVAC1 vaccine, an autologous dendritic cell vaccine targeting telomerase in AML patients, is the incorporation of the targeting sequence of the lysosomal associated membrane protein (LAMP) -1 into the mRNA dendritic cell loading sequence. LAMP technology is sub-licensed by ITI to Geron for use in telomerase cancer vaccine clinical trials.
Read more

Immunomic Therapeutics to Present at NY Keiretsu Chapter's Life Science Forum on November 18th.

November 9, 2009 ITI will be among the select few at this premier angel event to be held in New York on November 18th. The Keiretsu Forum is the largest group of accredited investors with 15 chapters located in the U.S. and overseas.
Read more

Immunomic Therapeutics Presents to Large Audience at Mid-Atlantic Bio 2009.

November 4, 2009 ITI was one of 14 regional companies selected to present at this year's conference as part of the Emerging Companies session at Mid-Atlantic Bio 2009. Dr. Bill Hearl presented ITI's corporate presentation to a full room and explained how ITI is going to maximize the value of the LAMP-vax platform by focusing on the large and growing opportunity in allergy.
Read more

New Publications Highlight Effectiveness of LAMP Technology.

October 28, 2009 ITI reports on two new publications in the literature with applications of LAMP showing excellent results. One study demonstrates the utility of the LAMP construct in providing protection for rabies and a second reports on use as an alternative to live attenuated yellow fever vaccine.
Read more

Immunomic Therapeutics names Winston Lowe III Corporate Counsel and Secretary of ITI.

September 18, 2009 The Board of Directors is pleased to announce the appointment of Winston Lowe III, of WinstonLowe LLC, as Immunomic Therapeutics Corporate Counsel and Secretary to the Board. Mr. Lowe bring an enormous amount of experience and credibility to ITI; everyone at ITI is very pleased to have him joining our team.
Read more

Immunomic Therapeutics Appoints Bernard C. Rudnick Chief Financial Officer

September 18, 2009 The Board of Directors is pleased to announce the appointment of Mr. Bernard C. Rudnick to the post of Chief Financial Officer. Mr. Rudnick is an experienced financier and corporate executive; Mr. Rudnick has been active in the Company since its inception and will bring his exceptional skills in finance and business modeling to ITI's management team.
Read more

Immunomic Therapeutics Presents Company in BioBusiness Forum at Bio 2009 in Atlanta

May 19, 2009 ITI presented the Company at the 2009 International Bio Convention as part of the BioBusiness Forum. The company was also an active participant in the Partnering Sessions offered at Bio. Dr. Hearl is optimistic that the connections made at this meeting will help accelerate the development of LAMP vaccines.
Read more

Immunomic Therapeutics Hold Successful Pre-IND Meeting for JRC-LAMP-vax Vaccine.

March 15, 2009 Immunomic Therapeutics, Inc. announced today that it completed a successful pre-IND meeting for the Phase Ia / Phase Ib clinical study of JRC-LAMP-vax, a vaccine for use in allergy immunotherapy targeting Japanese red cedar, the #1 seasonal allergen in Japan.
Read more

PREVIOUS PRESS RELEASES ARCHIVE - 2008

Immunomic Therapeutics Announces It is Seeking Pre-IND Meeting for Red Cedar Allergy Vaccine

November 17, 2008 Immunomic Therapeutics has submitted a request to hold its second pre-IND meeting; this one is to support a future clinical trial planned for its innovative allergy vaccine targeting Japanese Red Cedar, JRC-LAMP-vax. The Company hopes to be ready to file the IND before the end of 2009.

Allergy Expert Dr. Larry Weiner Joins ITI's Advisory Board

November 5, 2008 Immunomic Therapeutics is pleased to announce that Dr. Larry Weiner, an expert in the field of allergy and allergy therapy, has agreed to join the Scientific Advisory Board of ITI effective immediately. Dr. Weiner is expected to provide key guidance and support to the Company's planned clinical trial in the field of allergy immunotherapy.

Immunomic Therapeutics Will Be Presenting a Poster at the Philadelphia - Japan Health Sciences Dialog, October 20-21, 2008

September 22, 2008 Immunomic Therapeutics, Inc. announced today that the company will be presenting at the Philadelphia - Japan Health Sciences Dialog - New Directions in Vaccines next month in Philadelphia.

Immunomic Therapeutics Announces Plans to Seek Pre-IND Meeting on Allergy

September 18, 2008 Immunomic Therapeutics, Inc. announced today that the company will be requesting its second pre-IND meeting to discuss its planned clinical trials for short ragweed and Japanese red cedar.

Bruce Mackler & W. Barry McDonald Increase Role in Management of ITI

August 15, 2008 Dr. Bruce Mackler and Mr. Barry McDonald, current members of ITI's Board of Directors will be increasing their role in ITI under the direction of CEO, Dr. Bill Hearl. Mr McDonald has extensive experience as a business development consultant especially in the area of allergy and Dr. Mackler is an expert in regulatory affairs. They expand the business capabilities of ITI significantly.

Immunomic Therapeutics Hold Successful Pre-IND Meeting on Argotom-VAX Therapeutic HIV Vaccine.

April 8, 2008 Immunomic Therapeutics, Inc. announced today that it completed a successful pre-IND meeting for the Phase I clinical study of Argotom-VAX, a therapeutic HIV vaccine. ITI is acting at the IND sponsor for the collaborative research partner on this project, Genoa Biotec.

Immunomic Therapeutics Selected to Present at Two Venture Fairs in April

March 15, 2008 Immunomic Therapeutics, Inc. announced today that the company has been selected to present at the 3 Rivers Venture Fair and the Philadelphia Angel Venture Fair

Immunomic Therapeutics Files Materials for Pre-IND Meeting on Argotom-VAX, a Therapeutic Vaccine for HIV

March 10, 2008 Immunomic Therapeutics, Inc. announced today that it has completed its data packet filing in support of the Company's first pre-IND meeting. The packet was filed as part of the process leading up to a Phase I clinical study of ITI's & Genoa's therapeutic HIV vaccine, Argotom-VAX.

PREVIOUS PRESS RELEASES ARCHIVE - 2007

Immunomic Therapeutics Named Top Presenting Company at Bio-Life-Tech 2007

December 12, 2007 Immunomic Therapeutics, Inc. was selected as the top presenting company at Early Stage East's Bio-Life-Tech 2007 winning the "Company Most Likely to Receive Funding" Award.

Immunomic Therapeutics and Genoa Biotecnologia, S.A. Sign Collaborative Research Agreement to Study Therapeutic HIV Vaccines in Phase I/II Clinical Trial

September 17,2007 ITI announced today that the Company has entered into a Collaborative Research Agreement with the Brazilian biotechnology company, Genoa Biotecnologia, S.A. The Agreement will be bringing together scientists from the two companies plus researchers at Johns Hopkins University and the Universidade de Sгo Paulo to study a novel therapeutic vaccine in patients with HIV.

Immunomic Therapeutics Invited to Present an Update at Mid-Atlantic Diamond Ventures Event

September 15, 2007 Immunomic Therapeutics, Inc. announced today that the company has issued a sub-license to the LAMP technology to the Geron Corporation (see www.geron.com) for use in its cancer vaccine program.

Rathmann Foundation Invests in ITI

July 12, 2007 Immunomic Therapeutics, Inc. announced today that the Rathmann Foundation will be making an investment in the Company.

Immunomic Therapeutics Selected to Present at Three Investor Conferences

March 19, 2007 The Company announced today that ITI has been selected to present at three important investor conferences: the Philadelphia Angel Venture Fair, the Annual Conference of Bio (Bio 2007) and the World's Best Technology Showcase.

Immunomic Therapeutics Selected to Present at Mid-Atlantic Diamond Ventures Event

January 12, 2007 The Company announced today that ITI has been selected to present at Temple University's Mid-Atlantic Diamond Ventures meeting in February 2007.

Immunomic Therapeutics Awarded TEDCO Grant to Study Methods of Delivery of LAMP - Based DNA Vaccines

January 2, 2007 The Company announced today that ITI has been awarded a $75,000 project award from TEDCO to study options for delivery of LAMP-based DNA vaccines.

PREVIOUS PRESS RELEASES ARCHIVE - 2006

Immunomic Therapeutics And The Geron Corporation Release Joint Statement Announcing Licensing Deal

November 5, 2006 Immunomic Therapeutics, Inc. announced today that the company has issued a sub-license to the LAMP technology to the Geron Corporation (see www.geron.com) for use in its cancer vaccine program.

Immunomic Therapeutics Selected to Present at the National Showcase of University Start-Ups

October 10, 2006 Immunomic Therapeutics, Inc. (ITI, www.immunomictherapeutics.com) announced today that the company was selected as a presenting company at the inaugural National Showcase of University Start-Ups sponsored by the National Council for Entrepreneurial Tech Transfer (www.ncet2.org).

Immunomic Therapeutics Receives Grant to Attend Mid-Atlantic Venture Conference

October 4, 2006 Immunomic Therapeutics, Inc. announced today that received an award to attend the Mid-Atlantic Venture Conference in Philadelphia this week.

Immunomic Therapeutic Announces Exclusive License Agreement with Johns Hopkins University for LAMP Technology

October 2, 2006 Immunomic Therapeutics, Inc. (ITI, www.immunomictherapeutics.com) announced today that it has acquired the worldwide exclusive rights to the LAMP Vaccine technology from Johns Hopkins University.

Immunomic Therapeutics Signs Option Agreement with Johns Hopkins University for LAMP Technology

March 15, 2006 Immunomic Therapeutics, Inc. (ITI, www.immunomictherapeutics.com) announced today that it has acquired an interest in LAMP Vaccine technology by signing an Option to License Letter with Johns Hopkins University.

Immunomic Therapeutics Begins Operations in Earnest; Looks Forward to 2006.

Gaithersburg, MD, January 2, 2006 /-- Immunomic Therapeutics, Inc. (ITI, www.immunomictherapeutics.com) announced today that it is officially starting operations today and that it has appointed Dr. Bill Hearl, most recently the Chief Scientific Officer of Capital Genomix, to be the President and CEO of ITI.